Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lyman GH et al. - Pegfilgrastim was cost-saving compared with 11-day filgrastim and cost-effective compared with 6-day filgrastim from a health payer's perspective for the primary prophylaxis of FN in these women with early-stage breast cancer receiving myelosuppressive chemotherapy.

Related Articles

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09    Relevance Score: 74%

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09    Relevance Score: 72%

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09    Relevance Score: 72%

Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09    Relevance Score: 72%

Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09    Relevance Score: 72%

Today in Pharmacoeconomics...keeping you current

Costs of hospital-based methadone maintenance treatment in HIV/AIDS control among injecting drug users in Indonesia
Health Policy, 12/16/09

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Cost Effectiveness and Resource Allocation, 12/15/09

Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden
Current Medical Research and Opinion, 12/14/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address